Page 7 - Mandy Fahey News Today

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) News provided by Share this article Share this article BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmeds Compensation Comm...

Message : Required fields BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmeds Compensation Committee and made as a material inducement to each employees entry into employment with the Company. I...

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference -Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease- -Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high num...

Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters Options to Purchase Additional Shares and Notes News provided by Share this article Share this article BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its common stock (the "Shares"), including 1...

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 News provided by Share this article Share this article BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and a registered un...

Insmed Reports First Quarter 2021 Financial Results and Provides Business Update --ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen-- --ARIKAYCE European Launch Under Way with Commercial Sales in Germany and the Netherlands-- --Enrollment Progresses in Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis and in Post-Marketing ARISE and...